Multiple Myeloma

Clifton Mo, MD, presents data from the INSURE study, a pooled analysis evaluating patients with relapsed/refractory multiple myeloma treated with Ixazomib-Lenalidomide-Dexamethasone (IRd).

Steven Frommeyer introduces the two teams of competing physicians participating in Cancer Network® Face-off.

Two experienced clinicians share their thoughts on the safety of selinexor, including how they optimize dosing to prioritize patient comfort.

Dr Mikhael and Dr Kaya discuss the clinical implications and share their thoughts on the use of selinexor, carfilzomib and dexamethasone in patients with R/R MM.

Drs Sidana and Silbermann describe the currently available treatment options for early- and late-relapse MM, and how to select an appropriate regimen.

Dr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.

An explanation of the mechanism of action of bispecific antibodies and their use in relapsed/refractory multiple myeloma treatment.

GPRC5D appears to be an active, promising target for CAR T-cell product MCARH109 in heavily pretreated multiple myeloma.

Joseph Mikhael, MD, in a conversation on important presentations from the 2022 International Myeloma Society Annual Meeting, highlighted key findings with lenalidomide plus RVd and stem cell transplant in patients with high-risk multiple myeloma.

This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.

Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.

Joseph Mikhael, MD, provides a brief overview of the relapsed/refractory multiple myeloma landscape and explains the mechanism of action of selinexor.

Insights on supportive care measures to minimize or counter common adverse effects for patients with R/R MM taking selinexor-based therapies

Closing out the program, Dr Ajay Nooka comments on the structural and biological disparities of care in multiple myeloma between Black and Caucasian patients, including age of presentation, delay of diagnosis and treatment, access to treatment options, and treatment response.

A look at some of the unmet needs in transplant-eligible multiple myeloma, particularly within the high-risk patient population.

Ajay Nooka, MD, and Matthew James Pianko, MD, discuss how they risk stratify patients with transplant-eligible multiple myeloma and the corresponding treatment approaches.

Discourse centered around dosing strategies for selinexor-based therapies.

Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.

Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.

Dr Matthew James Pianko details how he determines treatment duration and discontinuation for transplant-eligible multiple myeloma.

Joseph Mikhael, MD, spoke about the mechanism of action of bispecific antibody teclistamab relative to other agents in the space such monoclonal antibodies and CAR T-cell therapies in multiple myeloma.

Following the 2022 American Society of Clinical Oncology Annual Meeting, experts in multiple myeloma discuss real-world evidence as it relates to the present-day treatment of patients.

Minimal residual disease negativity might be an important prognostic indicator in patients with newly diagnosed multiple myeloma, investigators say.

Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.

Andrew Cowan, MD, presents the results of the ENDURANCE study comparing two triplet regimens in transplant-ineligible MM.